about
Ridinilazole: a novel therapy for Clostridium difficile infectionA blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacyShoe soles as a potential vector for pathogen transmission: a systematic review.Intravenous azithromycin.Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.Education, training, and academic experience of newly hired, first-time pharmacy faculty members.Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, TexasImpact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.Crofelemer for the treatment of secretory diarrhea.Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases.Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics.Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology.Identification of toxemia in patients with Clostridium difficile infection.A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection.Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile.Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole.Pharmacists' perceptions of the effectiveness of antimicrobial control programs.Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic.Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire.Colonic immunopathogenesis of Clostridium difficile infections.Significant publications on infectious diseases pharmacotherapy in 2009.Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.Treatment of Candida famata bloodstream infections: case series and review of the literature.Impact of a pharmacotherapy alerting system on medication errors.Agreement among measurements and estimations of glomerular filtration in children with cancer.Mechanisms for floor surfaces or environmental ground contamination to cause human infection: a systematic review.Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples.Investigation of potentially pathogenic Clostridium difficile contamination in household environs.Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests.Echinocandin use in hospitalized patients: a multi-institutional study.T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial.Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship.Host factors and clinical outcomes of Candida colonization in critically ill patients.Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus.Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas.Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital.Economic consequences of unused medications in Houston, Texas.
P50
Q26747248-194FD309-4547-4DF8-BAAD-6EF454156A68Q26823657-96F4B9C9-3D0E-4693-B613-D693A23FB55FQ30244373-BF315CF3-0AFA-4363-B555-AE000761BD8FQ33543121-F72B7E34-69B0-463E-B480-91D68AEA677DQ33738775-3DFC4F88-F8DE-46FB-AF5A-E1B20B88D144Q33781828-65F5DE0D-C922-4610-A94A-1A86FA05C81AQ33945833-B213A827-0858-43BF-9615-0346358360CBQ34108708-C414555A-A699-4AA4-B7F1-8BED64E02A4BQ34239002-3E860802-6DCC-43D1-B6FB-DCDADE7E9F11Q35044951-5FE1C10E-0444-47F3-BA20-239F1297D706Q35136379-01BB9458-F8DF-4963-A820-6BAC24A4D807Q35193241-9A431793-3510-4A65-B3AC-B1D6D149A60EQ35465119-DDF98B12-45F3-44B4-B72A-F324C5A188FBQ35532908-27DD358B-39A5-4E6F-80BE-972727942427Q35960887-480F97E9-CE3E-4CC3-8790-A0EE69F946C1Q35997593-36E601D8-E92C-451F-84CB-C1A676C4F610Q36075884-1F34D975-3C94-418A-97BF-788F0A7A1100Q36678715-9774D511-673F-4E2A-B88D-EF7AEC65B13CQ36802575-DB3920D6-A7BB-4565-B148-CDA29FA320F0Q37026639-7D4D683E-981A-4FF2-9592-A868E66683A9Q37162353-28A28983-1899-4A4B-89B1-0700D5F6D4EFQ37712845-38773673-B260-47CB-9F17-9E41773BCA58Q37774819-D521D131-FD6B-4506-B07D-689682E2AE6CQ38027469-A2608C62-E379-49D5-AADF-C08E39F71FDBQ38053851-8A7EB612-9C1C-40C3-8E6D-08E6688DC948Q38069366-06F2C377-D090-4C3D-AF9F-B5F2513D0D22Q38255053-E79E6627-34D3-4CD2-BFA3-E63D6863FC46Q38990608-E05FFFF1-6EEF-4176-BA0F-2319DA383BF9Q39422769-2F053D0C-97C0-4707-8917-AC62A03FB0BDQ40179294-871BB5C7-6A3D-4A11-A70B-4D735D853F5AQ41217600-6A3440D6-4B6A-4B91-B16F-080E2F1FF722Q41530615-8A85C92D-8917-415D-A5B0-17FCD534D632Q41546170-1CAE219B-EAAB-488C-95A3-DA07E571E72BQ41637316-3EE63F15-0054-433F-BE3E-A8A278CFA508Q41760658-8C82E6E5-22A8-4065-9687-76BDB33BC6D7Q42001100-4EA2A579-17EA-4152-89CC-E45711F9B331Q42910111-E7B06DF2-FBF3-4CB2-B31D-7868166486E1Q43114420-3C9FA068-2692-4668-A04F-C1DEA30B7879Q43297981-D4DBAE2E-E437-46FC-9FF6-CE083B4FC8DBQ43311197-4B622DA9-2554-49F4-9A63-55F05DA0D79A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kevin W. Garey
@ast
Kevin W. Garey
@en
Kevin W. Garey
@es
Kevin W. Garey
@sl
type
label
Kevin W. Garey
@ast
Kevin W. Garey
@en
Kevin W. Garey
@es
Kevin W. Garey
@sl
prefLabel
Kevin W. Garey
@ast
Kevin W. Garey
@en
Kevin W. Garey
@es
Kevin W. Garey
@sl
P106
P1153
6603699736
P21
P31
P496
0000-0003-2063-7503